Showing 251-260 of 1716 results for "".
Burnout: Is Personal Happiness the Answer?
https://practicaldermatology.com/programs/practical-dermatology/burnout-is-personal-happiness-the-answer/18191/Physician burnout remains a conversation, and the pandemic dramatically changed the landscape for dermatologists—for better and for worse. Omaha, NE-based Joel Schlessinger, MD, who serves as Chief Cosmetic Surgery Editor of Practical Dermatology® speaks with Las Vegas-based dermatologist H.L. GreenScientifically Speaking: Investing in Innovation with Humberto Antunes
https://practicaldermatology.com/videos/scientifically-speaking/scientifically-speaking-investing-in-innovation-with-humberto-antunes/20128/With decades of experience in dermatology and aesthetics, Humberto Antunes has helped to identify some key innovations in the field. Now part of Gore Range Capital, he continues to look for the next game-changer. He discusses his experience and shares insights on the specialties with host Joel L. CoContent marketing in the age of COVID 19
https://practicaldermatology.com/topics/practice-management/content-marketing-in-the-age-of-covid-19/19836/COVID-19 has changed everything, probably including the way you promote your practice. Content marketing has become more challenging, and more important than ever. Check out this short video from Ekwa Marketing to learn what to do (and what not to do) for a successful content marketing strategy.Re-introducing Ortho Dermatologics, Tremfya Approved, Obagi Acquired
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-re-introducing-ortho-dermatologics-tremfya-approved-obagi-acquired/18458/Valeant Pharmaceuticals is changing the name of its dermatology division to Ortho Dermatologics. In an exclusive interview with DermWireTV, Executive Vice President and dermatology industry veteran William Bill Humphries discusses the change. The FDA has approved Janssen Biotech's Tremfya (guselkumaElections and Markets, Encore and Biofrontera Launches, More
https://practicaldermatology.com/topics/practice-management/dermwiretv-elections-and-markets-encore-and-biofrontera-launches-more/18564/Election years bring market uncertainty, but should you be making any changes to your portfolio now? Financial experts weigh in on why—no matter the results—there's no need for panic. Allergan launches a new campaign, ActuallySheCan, to empower young women. Several new products are now available forSEO Playbook: On-Page Factors
https://practicaldermatology.com/topics/practice-management/seo-playbook-on-page-factors/18994/Internet marketing is constantly changing--especially when it comes to SEO. Learn how on-page factors like Content, HTML, and architecture affect SEO and the marketing value of your practice website.Injectable Pearl: Microcannulas
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/injectable-pearl-microcannulas/19087/The microcannula is changing the art of aesthetic injectables but it's not right in very situation. Key to success is knowing when to use the cannula versus a needle, says Julius Few, MD.Refining Risk Stratification in Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/programs/practical-dermatology-updates-in-skin-cancer/refining-risk-stratification-in-cutaneous-squamous-cell-carcinoma/54650/Gaurav Singh, MD, MPH, FACMS, discusses what changed with the new integrated 40-gene expression (i40-GEP) test and how much these changes have refined the clinical performance.Expanding the Role of Topicals in Atopic Dermatitis
https://practicaldermatology.com/programs/practical-dermatology-updates-in-atopic-dermatitis/expanding-the-role-of-topicals-in-atopic-dermatitis/57282/Tina Bhutani-Jacques, MD, MAS, discusses how newer nonsteroidal topical therapies are changing the treatment paradigm in atopic dermatitis, expanding options for patients across disease severities and supporting long-term disease management.The Emergence of Targeted Therapies for Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.